期刊文献+

不稳定型心绞痛患者同型半胱氨酸水平变化及宁心汤对其的影响 被引量:2

下载PDF
导出
摘要 目的观察宁心汤治疗不稳定型心绞痛的疗效及其对同型半胱氨酸(Hcy)水平的影响。方法将70例不稳定型心绞痛患者随机分为宁心汤组35例和常规药物组35例,两组均予西医常规治疗,宁心汤组加服中药,两组疗程均为30d。观察两组治疗后心绞痛发作次数,心电图疗效、硝酸甘油的用量、调节血脂代谢及采用高效液相色谱法检测血清中Hcy含量。结果治疗组在心绞痛发作次数、心电图疗效、硝酸甘油用量、血清Hcy含量变化均明显优于对照组(P<0.05)。结论 Hcy对不稳定型心绞痛(UAP)具有早期诊断和鉴别诊断价值;宁心汤结合西药治疗确为治疗不稳定型心绞痛的有效方法之一。
出处 《中国中医药现代远程教育》 2013年第23期12-13,共2页 Chinese Medicine Modern Distance Education of China
  • 相关文献

参考文献11

  • 1陆再英.内科学[M].7版.北京:人民卫生出版社,2011:936.
  • 2Chan A, Qiao M, Chook P, et al. Hyperhomocysteinaemia is correlated to severity and extent of coronary artery diseaseEJ]. Am Coil Cardiol,2002,39(4) :141B.
  • 3Kullo U,Li G,Bielak LF,et al. Association of plasma homocysteinen with coro- nary artery calcification in defferent categories of coronary heart disease risk[J]. Mayo Clin Proc,2006,81(2):177-182.
  • 4Chan A, Qiao M, Chook P,et al. Hyperhomocysteinaemja is an independent risk factor for acute myocardial infarction in coronary patients:an emerging strategy for secondary prevention[J]. Am Coil Cardiol,2002,39(10) :131.
  • 5不稳定性心绞痛诊断和治疗建议[J].中华心血管病杂志,2000,28(6):409-412. 被引量:2696
  • 6中华人民共和国卫生部.中药(新药)临床研究指导原则[S].1993,46.
  • 7中华人民共和国卫生部医政司.中国常见心脑血管疾病诊断指南[S].北京:科学出版社,2000:59-60.
  • 8姜德谦,文丹,周胜华.低分子肝素治疗不稳定性心绞痛的临床观察[J].湖南医科大学学报,2001,26(4):340-342. 被引量:12
  • 9McCally KS. Homocysteine and vascular disease[J]. Nature Med, 1996,2 (4): 386-389.
  • 10阴健,郭力弓.中药现代研究与lI缶床应用[M].北京:学苑出版社.1995:251-261.

二级参考文献9

  • 1[1]The TIMI Ⅲ B investgators. Effects of tissue plasminogen activator and comparison of early invasive and conservative strategies in unstable angina and Non-Q-Wave myocardial infarction: Results of the TIMI ⅢB Trial[J]. Circulation, 1994,89:1545-1556.
  • 2[2]The global use of strategies to open occluded coronary arteries (GUSTO) Ⅱ. A investigators: Randomized trial of intravenous heparin Versus recombinant hirudin for acute coronary syndromes[J]. N Engl J med, 1996, 335:775-782.
  • 3[3]Fragmin during instability in coronary artery disease (FRISC) study group. Low molecular weight heparin during instability in coronary artery disease[J]. Lancet, 1996,347:561-567.
  • 4[4]Mizunok, Satumorak, Miyamoto HE, et al. Angioscopic evaluation of coronary artery thrombi in acute coronary syndromes[J]. N Engl J Med, 1992,326:387-391.
  • 5[5]Drieger D, Dawes J. Long term persistence of biological activity follawing administration of Enoxaparin sodium (clexane) is due to sequestration of antithrombin-Blinding low molecular weight fragments-comparison with unfractionated heparin[J]. Thromb Haemost, 1996,75:740-746.
  • 6[6]Tcheng JE, Harrington RA, Marchant KK, et al. Multicenter, randomized, doublebind, placebo-controlled triall of the platelet integrin glycoprotein Ⅱb/Ⅲa blocker integrelin in elective coronary intervention[J]. Circulation, 1995,91:2151-2157.
  • 7[7]Lassen MR, Borris LC, Anderson BS, et al. Efficacy and safety of prolonger thromboprophylaxis with a low molecular weight heparin after total hip arthroplasly[J]. Thrombosis Research, 1998,89:281-287.
  • 8[8]Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin Versus regular heparin on asprin in the treatment of unstable angina and. Silent ischemia[J]. J AM Coll Cardiol, 1995,26:313-317.
  • 9[9]Lindahl B, Veuge P, Wallentin, et al. Troponin T identifies patients with unstable coronary artery disease who benifit form long-term antithromobotic protection[J]. (FRISC study) J AM Coel Cardiol, 1997,29:43-48.

共引文献2890

同被引文献21

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部